Science News Hubb
Advertisement
  • Home
  • Science News
  • Technology
  • Contact us
No Result
View All Result
  • Home
  • Science News
  • Technology
  • Contact us
No Result
View All Result
Science News Hubb
No Result
View All Result
Home Science News

Malaria vaccine: Ghana is the first country to approve highly effective R21/Matrix-M

admin by admin
April 14, 2023
in Science News


A nurse administering a vaccine to a child in Ghana in 2019

AFP via Getty Images

Ghana is the first country to approve a new, highly effective malaria vaccine called R21/Matrix-M. The decision marks a milestone in the efforts to combat a disease that killed 619,000 people in 2021, most of them young children.

The country’s Food and Drugs Authority authorised the shot on 13 April for children between the ages of 3 and 5 years old – the age group most vulnerable to dying from malaria in areas with high transmission rates. A majority of countries in Africa, including Ghana, account for 95 per cent of all malaria cases worldwide, and 96 per cent of deaths. Children under 5 account for 80 per cent of deaths in the region, according to the World Health Organization (WHO).

Immunisation with the recently approved vaccine involves three primary doses followed by a booster shot one year later. While the vaccine’s phase III trial is still ongoing, an earlier phase II trial conducted in 2019 found it was 77 per cent effective at preventing infection. The only other approved malaria vaccine – Mosquirix, manufactured by UK pharmaceutical company GSK – is about 30 per cent effective at protecting against severe illness.

R21/Matrix-M is the first vaccine to exceed the WHO’s malaria vaccine efficacy goal of 75 per cent. The WHO has not yet approved it, but according the BBC, the organisation is reviewing data from the ongoing phase III trial involving 4800 children. The drug’s developer, the University of Oxford, is expected to report data on that trial later this year.

The drug’s manufacturer, the Serum Institute of India, said in a press release that it has the capacity to produce more than 200 million doses of the drug annually – significantly more than the 15 million yearly doses of Mosquirix promised by GSK.

“Malaria is a life-threatening disease that disproportionately affects the most vulnerable populations in our society and remains a leading cause of death in childhood,” said Adar Poonawalla at the Serum Institute of India in a press release. “The licensure of the R21/Matrix-M for use in Ghana is a significant milestone in our efforts to combat malaria worldwide.”

Topics:



Source link

Tags: Africamalariapublic healthvaccines
Previous Post

New Carl Sagan documentary in the works from NatGeo and Seth MacFarlane

Next Post

Hibernating bears don’t get blood clots. Now scientists know why

Next Post

Hibernating bears don't get blood clots. Now scientists know why

Recommended

New Planet-Hunting Technique Finds Worlds We Can See Directly

April 14, 2023

Psychedelics may improve mental health by getting inside nerve cells

February 17, 2023

Don't miss it

Science News

Why the 2023 Atlantic hurricane season is especially hard to predict

May 27, 2023
Science News

IBD: We may finally know why psychological stress worsens gut inflammation

May 27, 2023
Science News

Disney’s Star Wars: Galactic Starcruiser hotel will go Dark (Side), cease operations

May 27, 2023
Technology

Thousands of New Creatures Discovered in Deep-Sea Mining Zone

May 27, 2023
Technology

With Winds at 175 Miles Per Hour, and Gusts Near 210, Super Typhoon Mawar Is Earth’s Strongest Storm of 2023

May 27, 2023
Technology

Breaking Down Proteins to Build Food Waste Solutions

May 27, 2023

© Science News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Science News
  • Technology
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • Science News
  • Technology
  • Contact us

© 2022 Science News Hubb All rights reserved.